Phase 1 publication is a scientific milestone but does not change the binary risk profile. The next major catalyst is AURA Phase 2 topline data in late 2027. Monitor enrollment updates and any early safety signals.
Price Chart
Executive Summary
Avalyn Pharma published detailed Phase 1 data for AP02 (nebulized nintedanib) in Respiratory Research, showing substantially higher predicted lung exposure and 10- to 56-fold lower systemic exposure versus oral nintedanib. The data support the ongoing AURA Phase 2 trial in IPF, with topline results expected in late 2027. This is a positive scientific validation but a routine clinical-stage update with no binary catalyst near-term.
Key Facts
- Phase 1 data published in Respiratory Research show AP02 achieved ~26-fold higher predicted nintedanib lung exposure (Cmax, AUC0-12) vs oral nintedanib 150mg.
- AP02 resulted in 10- to 56-fold lower systemic exposure than the approved 150mg BID oral nintedanib dose.
- No serious adverse events reported; most common TEAEs were headache, nausea, mild cough, and dizziness.
- AURA Phase 2 trial (n=160, 12-week, placebo-controlled) is enrolling; topline data expected late 2027.
- AP02 is an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis (IPF).
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Phase 2 trial may fail to meet efficacy endpoints; IPF trials have high failure rates.
- Competition from oral nintedanib (Ofev) and other inhaled therapies in development.
- Long timeline to data (late 2027) with no near-term revenue or regulatory catalyst.
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365508 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | Press Release | $31.62 $28.32 | ▼ −10.44% | ▼ −9.42% | $27.24 (−13.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $38.25 $37.69 | ▼ −1.46% | ▼ −0.27% | $27.24 (−28.78%) |
Aug 12, 2026 10w ago | 8-K | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.24 (−27.13%) |
Aug 12, 2026 10w ago | Press Release | $37.38 $38.97 | ▲ +4.25% | ▲ +4.70% | $27.24 (−27.13%) |
Jun 17, 2026 18w ago | 8-K | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.24 (−7.06%) |
Jun 17, 2026 18w ago | Press Release | $29.31 $30.09 | ▲ +2.66% | ▲ +3.70% | $27.24 (−7.06%) |
Jun 3, 2026 20w ago | 8-K | $26.40 $28.53 | ▲ +8.07% | ▲ +11.89% | $27.24 (+3.18%) |
May 5, 2026 24w ago | Press Release | $27.71 $29.90 | ▲ +7.90% | ▲ +6.77% | $27.24 (−1.70%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.24 (−6.30%) |
May 1, 2026 25w ago | Insider Cluster | $29.07 $29.57 | ▲ +1.72% | ▼ −1.25% | $27.24 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers